14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.83 $2.51 Friday, 3rd May 2024 CGEN stock ended at $2.11. This is 2.31% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 7.51% from a day low at $2.07 to a day high of $2.22.
90 days $1.83 $3.03
52 weeks $0.530 $3.03

Historical Compugen Ltd. prices

Date Open High Low Close Volume
Mar 30, 2023 $0.700 $0.740 $0.700 $0.720 161 172
Mar 29, 2023 $0.721 $0.740 $0.701 $0.712 186 109
Mar 28, 2023 $0.710 $0.740 $0.705 $0.721 97 361
Mar 27, 2023 $0.740 $0.740 $0.711 $0.725 186 118
Mar 24, 2023 $0.740 $0.766 $0.700 $0.700 387 028
Mar 23, 2023 $0.770 $0.790 $0.712 $0.712 339 667
Mar 22, 2023 $0.770 $0.81 $0.760 $0.760 142 950
Mar 21, 2023 $0.730 $0.790 $0.701 $0.788 237 290
Mar 20, 2023 $0.700 $0.750 $0.690 $0.720 208 606
Mar 17, 2023 $0.746 $0.750 $0.680 $0.680 382 980
Mar 16, 2023 $0.760 $0.790 $0.735 $0.750 177 272
Mar 15, 2023 $0.748 $0.760 $0.734 $0.757 196 261
Mar 14, 2023 $0.740 $0.772 $0.733 $0.740 236 288
Mar 13, 2023 $0.750 $0.750 $0.723 $0.730 211 398
Mar 10, 2023 $0.749 $0.82 $0.740 $0.740 286 240
Mar 09, 2023 $0.80 $0.85 $0.750 $0.750 256 968
Mar 08, 2023 $0.84 $0.86 $0.81 $0.81 168 102
Mar 07, 2023 $0.88 $0.88 $0.84 $0.85 102 996
Mar 06, 2023 $0.84 $0.89 $0.84 $0.87 237 196
Mar 03, 2023 $0.81 $0.90 $0.774 $0.84 309 386
Mar 02, 2023 $0.790 $0.81 $0.780 $0.797 154 574
Mar 01, 2023 $0.80 $0.84 $0.771 $0.81 217 938
Feb 28, 2023 $0.770 $0.85 $0.770 $0.790 437 044
Feb 27, 2023 $0.760 $0.790 $0.750 $0.762 308 325
Feb 24, 2023 $0.737 $0.778 $0.680 $0.745 303 009
Click to get the best stock tips daily for free!

About Compugen Ltd.

Compugen Ltd. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi... CGEN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT